Mesoblast (MESO) Long-Term Investments (2018 - 2025)
Mesoblast (MESO) posted Long-Term Investments of $1.6 million for Q4 2025, up 11.74% sequentially from $1.4 million in Q2 2025, and up 28.39% YoY from $1.2 million in Q4 2024.
Analysis
Mesoblast (MESO) Long-Term Investments (2018 - 2025) Analysis & Trends
Mesoblast has reported Long-Term Investments for 9 years, with the latest figure at $1.6 million in Q4 2025.
- Quarterly Long-Term Investments rose 28.39% year-over-year to $1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.6 million (up 28.39% YoY) and the FY2025 annual result came in at $1.4 million, up 36.88% from the prior year.
- Long-Term Investments advanced to $1.6 million in Q4 2025 per MESO's latest filing, from $1.4 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $2.3 million in Q4 2021 and troughed at $826000.0 in Q4 2023.
- A 5-year average of $1.7 million and a median of $1.8 million in 2022 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2023 and 2024: Long-Term Investments tumbled 57.62% in 2023, then soared 46.25% in 2024.
- Over 5 years, Long-Term Investments stood at $2.3 million in 2021, then dropped by 16.96% to $1.9 million in 2022, then sank by 57.62% to $826000.0 in 2023, then soared by 46.25% to $1.2 million in 2024, then advanced by 28.39% to $1.6 million in 2025.
- According to Business Quant data, Long-Term Investments over the past three periods registered $1.6 million, $1.4 million, and $1.2 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -4.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.77 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 372.10 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 1.55 Mn |
| Jun 30, 2025 | 1.39 Mn |
| Dec 31, 2024 | 1.21 Mn |
| Jun 30, 2024 | 1.01 Mn |
| Dec 31, 2023 | 826,000.00 |
| Jun 30, 2023 | 1.76 Mn |
| Mar 31, 2023 | 2.03 Mn |
| Dec 31, 2022 | 1.95 Mn |
| Sep 30, 2022 | 1.84 Mn |
| Jun 30, 2022 | 1.76 Mn |
| Mar 31, 2022 | 2.03 Mn |
| Dec 31, 2021 | 2.35 Mn |
| Sep 30, 2021 | 2.23 Mn |
| Jun 30, 2021 | 2.08 Mn |
| Mar 31, 2021 | 1.98 Mn |
| Dec 31, 2020 | 1.90 Mn |
| Sep 30, 2020 | 1.95 Mn |
| Jun 30, 2020 | 1.87 Mn |
| Mar 31, 2020 | 1.77 Mn |
| Dec 31, 2019 | 1.67 Mn |